Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109863 · ClinicalTrials.gov registry record · Phase 2
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00109863 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants.
The verdict
NCT00109863, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanoma.
Interventions
- BIOLOGICAL hu14.18-IL2 fusion protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109863
The ClinicalTrials.gov registry entry for NCT00109863 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hu14.18-IL2 fusion protein is the first listed.
NCT00109863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109863 about?
NCT00109863 is a clinical study titled "Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma". RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanom...
What is the current status of trial NCT00109863?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00109863?
The interventions under investigation include: hu14.18-IL2 fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109863?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.